Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Observation Letters
87 (
4
); 542-544
doi:
10.25259/IJDVL_61_20

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by pirfenidone

Department of Dermatology, Medicine Hospital Universitario Ramón y Cajal. Madrid, Spain
Department of Intensive Care Medicine Hospital Universitario Ramón y Cajal, Madrid, Spain
Corresponding author: Dr. Dario de Perosanz-Lobo, Crta. Colmenar Viejo, Km 9100, Madrid-28034, Spain. dario.perosanz@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: de Perosanz-Lobo D, Fernández-Nieto D, Burgos-Blasco P, Aroca-Ruiz M, Fernández-Guarino M. Stevens-Johnson syndrome/toxic epidermal necrolysis induced by pirfenidone. Indian J Dermatol Venereol Leprol 2021;87:542-4.

Sir,

A 78-year-old woman presented with a 24 h history of a pruriginous cutaneous rash along with odynophagia and photophobia. She had a personal history of idiopathic pulmonary fibrosis (IPF) and had recently started therapy with pirfenidone (Esbriet®) two weeks ago. Besides pirfenidone, the patients' usual medications consisted of levothyroxine and pantoprazole as treatment for hypothyroidism and dyspepsia since many years. Physical examination showed an eruption of erythematous macules and papules with scarce incipient vesicles distributed over the patient’s trunk and proximal extremities. There was ophthalmological involvement with intense conjunctival hyperemia with pseudomembranes [Figure 1a]. Oral examination revealed extensive erosions on the buccal and palatal surfaces [Figure 1b]. The genital mucosa was not involved. Over the next few hours, the eruption evolved rapidly, becoming confluent. Dusky areas with epidermal detachment were observed [Figure 1c], while oral lesions extended to lingual and labial mucosae. A severe cutaneous adverse reaction to pirfenidone was suspected and a skin biopsy was performed. Histopathology revealed full-thickness epidermal necrosis with a minimal lymphocytic infiltrate in the dermis [Figure 2]. These findings were consistent with the diagnosis of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) related to pirfenidone. The patient was promptly transferred to a burn center with life support measures, including contact isolation and topical antibiotic to avoid superinfection. Pirfenidone administration was immediately withdrawn and subcutaneous etanercept 25 mg twice a week was initiated. This treatment has demonstrated an increased survival rate when administered early in suspected Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN).1 However, in this case, extensive blisters developed later over the patient’s back and chest, resulting in epidermal detachment of 15–20% of the total body surface area [Figure 3]. The patient required a three-month stay in the ICU until complete resolution of both cutaneous and mucosal lesions [Figure 4]. Etanercept administration was maintained until the end of therapy. During that time, no other medication was administered (cyclosporine nor steroids).

Figure 1a:: Physical examination 48 h after the onset of skin symptoms. Prominent conjunctival involvement with profuse secretion and crusting
Figure 1b:: Physical examination 48 h after the onset of skin symptoms. Extensive erosions on the palatal mucosa.
Figure 1c:: Physical examination 48 h after the onset of skin symptoms. Close up view of atypical targetoid lesions on the trunk with scarce areas of epidermal detachment
Figure 2:: Histopathological findings showing full-thickness epidermal necrosis with subepidermal detachment and minimal dermal inflammatory infiltrate (H&E, ×200)
Figure 3:: Physical examination 96 h after the onset of skin symptoms. Epidermal detachment (Pseudo-Nikolsky sign) in approximately 15–20% of the total skin surface, consistent with the diagnosis of Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN)
Figure 4:: Post-resolution image. Note the post-inflammatory hyperpigmentation

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease of unknown etiology. Despite its variable evolution, the median survival is only 2–3 years after the onset of symptoms. Pirfenidone is a novel orally administered pyridine with combined antifibrotic, antioxidant and anti-inflammatory actions. It has shown to reduce the decline in lung function and to prolong progression-free survival in these patients.2 Although the precise mechanism of action is unknown, it is thought to inhibit TGF-β and TNF-α and to reduce fibroblast proliferation and collagen synthesis.2,3 The most common adverse effects of pirfenidone include gastrointestinal symptoms, hepatic dysfunction and skin reactions. Among the latter, both “photosensitivity” and “skin rash” are listed as frequent side effects. Skin rash occurred in 11.6–32.2% of patients in different cohort studies and clinical trials, while photosensitive reactions were observed in 5.8– 12.2% of patients. Together photosensitivity and rash led to discontinuation of the drug in around 1–2%.4,5 However, little is known about categorization of this “rash” and “photosensitivity” reactions, since dermatological assessment has not been elaborated in the cited studies. TNF-α expression has been found to be elevated in plasma of Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) patients. This molecule seems to be key in the pathogenesis of this condition, since it can augment the granulysin expression which is the main mediator for keratinocyte detachment of the epidermis. Etanercept attenuates granulysin expression through blockade of the TNF-α associated pathway, being shown to be an effective treatment in Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN).1 Although the final evolution of our patient was favorable, she required a prolonged stay in the ICU for a complete recovery. Whether this could have been shortened if alternative options such as cyclosporine or steroids were adopted is a question to be considered, although it is also possible that, without the etanercept, the evolution to TEN would have been unstoppable.

In conclusion, we present a case of Stevens-Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) induced by pirfenidone. Dermatologists need to be aware that pirfenidone can be associated with potentially life-threatening skin reactions, since there has recently been an increase in its prescription. Cutaneous adverse effects related to this drug need also to be better characterized in further studies.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , , , et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128:985-96.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet. 2011;377:1760-9.
    [CrossRef] [Google Scholar]
  3. , , . Idiopathic pulmonary fibrosis. Lancet. 2017;389:1941-52.
    [CrossRef] [Google Scholar]
  4. , , , , , , et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP) Respiration. 2017;94:408-15.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Long-term safety of pirfenidone: Results of the prospective, observational PASSPORT study. ERJ Open Res. 2018;4:084-2018.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
3,964

PDF downloads
365
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections